

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An anhydrous form of sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Anhydrous Form B) having an X-ray powder diffraction pattern containing specific peaks at:  $3.8 (\pm 0.1^\circ)$ ,  $7.5 (\pm 0.1^\circ)$ ,  $11.2 (\pm 0.1^\circ)$ ,  $13.0 (\pm 0.1^\circ)$ ,  $13.8 (\pm 0.1^\circ)$ ,  $15.0 (\pm 0.1^\circ)$ ,  $15.7 (\pm 0.1^\circ)$ ,  $18.8 (\pm 0.1^\circ)$ ,  $20.2 (\pm 0.1^\circ)$ ,  $21.7 (\pm 0.1^\circ)$ ,  $22.6 (\pm 0.1^\circ)$  and  $30.2 (\pm 0.1^\circ)$   $2\theta$ .
2. (Original) An anhydrous form of sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Anhydrous Form C) having an X-ray powder diffraction pattern containing specific peaks at:  $4.3 (\pm 0.1^\circ)$ ,  $8.5 (\pm 0.1^\circ)$ ,  $14.6 (\pm 0.1^\circ)$ ,  $15.3 (\pm 0.1^\circ)$ ,  $16.1 (\pm 0.1^\circ)$ ,  $17.4 (\pm 0.1^\circ)$ ,  $18.7 (\pm 0.1^\circ)$ ,  $20.5 (\pm 0.1^\circ)$ ,  $22.1 (\pm 0.1^\circ)$ ,  $22.6 (\pm 0.1^\circ)$ ,  $23.1 (\pm 0.1^\circ)$  and  $29.6 (\pm 0.1^\circ)$   $2\theta$ .
3. (Original) A hydrated form of sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form A) having an X-ray powder diffraction pattern containing specific peaks at:  $4.2 (\pm 0.1^\circ)$ ,  $8.2 (\pm 0.1^\circ)$ ,  $8.5 (\pm 0.1^\circ)$ ,  $9.1 (\pm 0.1^\circ)$ ,  $11.5 (\pm 0.1^\circ)$ ,  $12.7 (\pm 0.1^\circ)$ ,  $14.8 (\pm 0.1^\circ)$ ,  $15.4 (\pm 0.1^\circ)$ ,  $16.6 (\pm 0.1^\circ)$ ,  $17.4 (\pm 0.1^\circ)$ ,  $17.7 (\pm 0.1^\circ)$ ,  $18.2 (\pm 0.1^\circ)$ ,  $20.4 (\pm 0.1^\circ)$ ,  $23.2 (\pm 0.1^\circ)$ ,  $29.1 (\pm 0.1^\circ)$  and  $29.8 (\pm 0.1^\circ)$   $2\theta$ .

4. (Original) A compound as claimed in claim 3 wherein the water of crystallisation is 3-10% w/w.
5. (Original) A hydrated form of sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form B) having an X-ray powder diffraction pattern containing specific peaks at: 4.5 ( $\pm 0.1^\circ$ ), 7.3 ( $\pm 0.1^\circ$ ), 8.3 ( $\pm 0.1^\circ$ ), 13.3 ( $\pm 0.1^\circ$ ), 14.5 ( $\pm 0.1^\circ$ ), 14.8 ( $\pm 0.1^\circ$ ), 15.4 ( $\pm 0.1^\circ$ ), 16.6 ( $\pm 0.1^\circ$ ), 18.7 ( $\pm 0.1^\circ$ ), 20.2 ( $\pm 0.1^\circ$ ), 21.1 ( $\pm 0.1^\circ$ ), 21.5 ( $\pm 0.1^\circ$ ), 21.9 ( $\pm 0.1^\circ$ ), 22.3 ( $\pm 0.1^\circ$ ), 23.5 ( $\pm 0.1^\circ$ ) and 24.9 ( $\pm 0.1^\circ$ )  $2\theta$ .
6. (Original) A compound as claimed in claim 5 wherein the water of crystallisation is 5-7% w/w.
7. (Original) A hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form C) having an X-ray powder diffraction pattern containing specific peaks at: 4.2 ( $\pm 0.1^\circ$ ), 7.5 ( $\pm 0.1^\circ$ ), 8.0 ( $\pm 0.1^\circ$ ), 11.4 ( $\pm 0.1^\circ$ ), 12.5 ( $\pm 0.1^\circ$ ), 15.1 ( $\pm 0.1^\circ$ ), 15.8 ( $\pm 0.1^\circ$ ), 17.7 ( $\pm 0.1^\circ$ ), 18.9 ( $\pm 0.1^\circ$ ), 20.5 ( $\pm 0.1^\circ$ ), 21.1 ( $\pm 0.1^\circ$ ), 22.7 ( $\pm 0.1^\circ$ ), 24.6 ( $\pm 0.1^\circ$ ), 26.1 ( $\pm 0.1^\circ$ ), 27.8 ( $\pm 0.1^\circ$ ) and 29.2 ( $\pm 0.1^\circ$ )  $2\theta$ .
8. (Original) A compound as claimed in claim 7 wherein the water of crystallisation is 3-10% w/w.
9. (Original) A hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form D) having an X-ray powder diffraction pattern containing specific peaks at: 8.8 ( $\pm 0.1^\circ$ ), 10.5 ( $\pm 0.1^\circ$ ), 11.8 ( $\pm 0.1^\circ$ ), 12.9 ( $\pm 0.1^\circ$ ), 15.6 ( $\pm 0.1^\circ$ ), 17.1 ( $\pm 0.1^\circ$ ), 18.9 ( $\pm 0.1^\circ$ ), 20.8 ( $\pm 0.1^\circ$ ), 23.3

- ( $\pm 0.1^\circ$ ), 25.6 ( $\pm 0.1^\circ$ ), 26.1 ( $\pm 0.1^\circ$ ), 26.9 ( $\pm 0.1^\circ$ ), 28.1 ( $\pm 0.1^\circ$ ), 30.6 ( $\pm 0.1^\circ$ ), 32.5 ( $\pm 0.1^\circ$ ) and 33.1 ( $\pm 0.1^\circ$ )  $2\theta$ .
10. (Original) A solvated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Solvated Form E) having an X-ray powder diffraction pattern containing specific peaks at: 3.6 ( $\pm 0.1^\circ$ ), 7.1 ( $\pm 0.1^\circ$ ), 8.3 ( $\pm 0.1^\circ$ ), 9.3 ( $\pm 0.1^\circ$ ), 9.8 ( $\pm 0.1^\circ$ ), 14.1 ( $\pm 0.1^\circ$ ), 15.9 ( $\pm 0.1^\circ$ ), 17.7 ( $\pm 0.1^\circ$ ), 18.6 ( $\pm 0.1^\circ$ ), 19.3 ( $\pm 0.1^\circ$ ), 21.7 ( $\pm 0.1^\circ$ ), 23.1 ( $\pm 0.1^\circ$ ), 24.1 ( $\pm 0.1^\circ$ ), 25.0 ( $\pm 0.1^\circ$ ), 25.8 ( $\pm 0.1^\circ$ ) and 26.3 ( $\pm 0.1^\circ$ )  $2\theta$ .
11. (Original) A crystalline form of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form A) having an X-ray powder diffraction pattern containing specific peaks at: 7.3 ( $\pm 0.1^\circ$ ), 8.5 ( $\pm 0.1^\circ$ ), 10.6 ( $\pm 0.1^\circ$ ), 13.4 ( $\pm 0.1^\circ$ ), 14.7 ( $\pm 0.1^\circ$ ), 15.4 ( $\pm 0.1^\circ$ ), 15.9 ( $\pm 0.1^\circ$ ), 19.9 ( $\pm 0.1^\circ$ ), 20.2 ( $\pm 0.1^\circ$ ), 21.7 ( $\pm 0.1^\circ$ ), 25.8 ( $\pm 0.1^\circ$ ) and 26.6 ( $\pm 0.1^\circ$ )  $2\theta$ .
12. (Original) A crystalline form of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form B) having an X-ray powder diffraction pattern containing specific peaks at: 9.9 ( $\pm 0.1^\circ$ ), 10.5 ( $\pm 0.1^\circ$ ), 11.0 ( $\pm 0.1^\circ$ ), 11.6 ( $\pm 0.1^\circ$ ), 13.3 ( $\pm 0.1^\circ$ ), 13.9 ( $\pm 0.1^\circ$ ), 14.9 ( $\pm 0.1^\circ$ ), 18.0 ( $\pm 0.1^\circ$ ), 19.0 ( $\pm 0.1^\circ$ ), 20.4 ( $\pm 0.1^\circ$ ), 22.2 ( $\pm 0.1^\circ$ ) and 23.0 ( $\pm 0.1^\circ$ )  $2\theta$ .
- 13-16. (Cancelled)
17. (Original) A process for preparing Anhydrous Form B comprising:
- drying a water-wet or hydrated form of a sample of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in the presence of phosphorus pentoxide under reduced pressure; or,

- b. heating a sample of Hydrate Form A from ambient temperature to 100°C.
18. (Original) A process for preparing Anhydrous Form C comprising heating a sample of Hydrate Form B from ambient temperature to 100°C.
19. (Original) A process for preparing Hydrate Form A comprising reacting 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine with 4-methylbenzenesulfonyl isocyanate in a suitable solvent at ambient temperature to form *N*-[[4-(3,4-dichlorophenoxy)][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in the suitable solvent; adding to that concentrated aqueous sodium hydroxide solution followed by water; and:
- a. stirring the resulting mixture to allow the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide, possibly contaminated with suitable solvent, to precipitate out with Hydrate Form A remaining after filtration and drying, or,
  - b. distilling the suitable solvent and allowing Hydrate Form A to precipitate from the aqueous.
20. (Original) A process for preparing Hydrate Form A comprising adding concentrated aqueous sodium hydroxide solution to a mixture of *N*-[[4-(3,4-dichlorophenoxy)][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in water at a temperature in the range 30-60°C and allowing the mixture to cool with the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide precipitating and Hydrate Form A remaining after filtering and drying.
21. (Original) A process for preparing Hydrate Form A as claimed in claim 20 comprising:
- a. mixing *N*-[[4-(3,4-dichlorophenoxy)][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide with water and heating the mixture to a temperature in the range 30-60°C; and,

- b. adding concentrated aqueous sodium hydroxide solution and allowing the mixture to cool with the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide precipitating and Hydrate Form A remaining after filtering and drying.
22. (Original) A process for preparing Hydrate Form A comprising adding concentrated aqueous sodium hydroxide solution to *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in a suitable organic solvent; heating the mixture and separating the aqueous layer; adding IMS and, optionally, toluene to the aqueous phase and cooling the resulting mixture; and, filtering off and drying the solid that forms.
23. (Original) A process for preparing Hydrate Form A comprising heating a mixture of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form B) and aqueous sodium hydroxide; cooling the mixture and extracting the cooled mixture with dichloromethane; combining the extracts; optionally reducing the volume of the combined organic extracts; cooling the dichloromethane mixture so that the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide precipitates; and, filtering off and drying the solid that forms.
24. (Original) A process for preparing Hydrate Form A comprising drying a sample of Hydrate Form D under reduced pressure at a temperature in the range 10-100°C.
25. (Original) A process for preparing Hydrate Form A comprising drying a sample of Solvated Form E at atmospheric pressure at a temperature in the range 0-30°C.

26. (Original) A process for preparing Hydrate Form B comprising mixing a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine in tetrahydrofuran with a solution of 4-methylbenzenesulfonyl isocyanate in tetrahydrofuran at a temperature in the range 15-35°C; adding aqueous sodium hydroxide solution and collecting the solid that precipitates.
27. (Original) A process for preparing Hydrate Form C comprising cooling a solution of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide in a mixture of water and acetone from reflux to around 0°C and collecting the solid product that forms.
28. (Original) A process for preparing Hydrate Form C comprising drying a sample of Solvated Form E reduced pressure at a temperature in the range 10-100°C.
29. (Original) A process for preparing Hydrate Form D comprising cooling a solution of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide in a mixture of water and 2-propanol from 50-80°C to 0-10°C and filtering off the residue.
30. (Original) A process for preparing Solvated Form E comprising cooling a solution of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide in a mixture of water, IMS and toluene from 50-80°C to 0-10°C and filtering off the residue.
31. (Original) A process for preparing *N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form A) comprising:

- a. purifying *N*-[[4-(3,4-dichlorophenoxy)-[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide using reverse phase chromatography eluting with a mixture of aqueous ammonia and acetonitrile; and,
  - b. freeze drying the fractions containing *N*-[[4-(3,4-dichlorophenoxy)-[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide and triturating the residue with acetonitrile and then drying the residue under reduced pressure at ambient temperature.
32. (Original) A process for preparing *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form A) comprising:
  - a. heating a mixture of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B and acetonitrile to 40-60°C; and,
  - b. drying the solid from the slurry so formed under reduced pressure.